NSCLC additional analyses and Real-world evidence

NSCLC additional analyses and Real-world evidence

Additional analyses on use of afatinib* in patients with non-small cell lung cancer (NSCLC), including subgroup analyses of clinical trial populations, special patient populations and real-world data

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2021 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: January 2021